Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by GrahamBon Apr 25, 2023 10:27am
212 Views
Post# 35412280

The other side of 74.5%

The other side of 74.5%
Just for balance, from the authors who conducted the research  of the key 2021 study:
 
Real-time 3D-echocardiography of the right ventricle—paediatric reference values for right ventricular volumes using knowledge-based reconstruction: a multicentre study:
While high accuracy and good reproducibility are some of the advantages of 3DE and KBR, we cannot deny that the feasibility of 74.5% demonstrated in our study is comparatively low.
This may be caused in part by the larger number of very young children included in our study population who were unable to cooperate fully or hold their breath during examination and in part by our relatively rigorous criteria, applied to make sure poor quality datasets were excluded to increase the reliability of the resulting reference values”
 
https://qims.amegroups.com/article/view/64967/html

It will be what it will be.
Good to hear of another conference-but will sign out and see all with financials release
GLTA
 
 
<< Previous
Bullboard Posts
Next >>